GSK plc
Financial Performance
GSK Revenue & Financials
Revenue
~$43.1B (FY2025)
Market Cap
$100B
Net Income
~$7.5B
Employees
66,800
What is GSK's revenue?
GSK had ~$43.1B in revenue for fiscal year 2025, up 4.1% from 2024. Net income was ~$7.5B.
- Latest revenue
- ~$43.1B (FY2025)
- Year-over-year
- +4.1%
- Growth rate (CAGR)
- 1.8% over 9 years
- Peak revenue
- ~$44.6B (FY2019)
- Years of data
- 10
- Employees
- 66,800
- How much profit does GSK make?
- GSK reported net income of ~$7.5B for fiscal year 2025. sec.gov
- How many employees does GSK have?
- GSK has about 66,800 employees.
Financial Analysis
GSK reported 2025 turnover of ~$43.2 billion (£32.7 billion) (+4% at actual rates, +7% at constant currency), operating profit of ~$10.4 billion (£7.9 billion), profit attributable to shareholders of ~$7.52 billion (£5.7 billion), and earnings per share of 141.1p. Cash generated from operations was ~$11.7 billion (£8.9 billion) and free cash flow ~$5.28 billion (£4.0 billion). In Q2 2026, sales rose 5% to ~$11.1 billion (£8.4 billion) and core operating profit rose 7% to ~$3.7 billion (£2.8 billion), beating consensus, while reported operating profit fell to ~$635 million (£481 million) because of the camlipixant impairment. H1 2026 turnover was ~$21.1 billion (£16.0 billion). GSK reaffirmed 2026 guidance of 3% to 5% turnover growth and 7% to 9% core operating profit growth, expects a 70p dividend for 2026, and launched a three-year plan targeting ~$2.51 billion (£1.9 billion) of annual savings by 2029. GSK plc is a colossal British multinational pharmaceutical and biotechnology company, commanding a market valuation typically exceeding $70 billion.
Revenue Trend Analysis
YoY Change
+4.1%
9-Year CAGR
+1.8%
Peak Year
2019
Trend
Consistent Growth
GSK plc has 10 full fiscal year figures on this page, compounding at +1.8% annually over 9 years. The most recent year saw a 4.1% increase versus the prior year. Annual revenue peaked in fiscal year 2019 at ~$44.6B. Of 9 comparable year-over-year steps, 8 showed growth and 1 showed a decline.
Annual revenue history
Click any row to see year details.
GSK plc balance sheet and cash flow
Balance-sheet figures are as of each fiscal year end; cash-flow figures cover the fiscal year. Taken from the company's annual report on Form 20-F, linked on each row. Free cash flow here is operating cash flow less capital expenditures, calculated by CorpDigest. In some years total assets exceed liabilities plus shareholders' equity because the company reported redeemable preferred stock or non-controlling interests outside both.
| Fiscal Year | Operating cash flow | Capital expenditures | Total assets | Total liabilities | Shareholders' equity | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | ~$10.2B | ~$1.8B | ~$80.7B | ~$59.6B | ~$21.6B | ~$8.4B | Form 20-F |
| FY2024ended Dec 31, 2024 | ~$8.7B | ~$1.8B | ~$78.5B | ~$61.2B | ~$18B | ~$6.8B | Form 20-F |
| FY2023ended Dec 31, 2023 | ~$8.9B | ~$1.7B | ~$77.9B | ~$61B | ~$17.6B | ~$7.2B | Form 20-F |
| FY2022ended Dec 31, 2022 | ~$9.8B | ~$1.5B | ~$79.4B | ~$66.1B | ~$14B | ~$8.3B | Form 20-F |
| FY2021ended Dec 31, 2021 | ~$10.5B | ~$1.3B | ~$104.4B | ~$76.2B | ~$19.9B | ~$9.2B | Form 20-F |
| FY2020ended Dec 31, 2020 | ~$11.1B | ~$1.3B | ~$106.2B | ~$78.7B | ~$19.3B | ~$9.8B | Form 20-F |
| FY2019ended Dec 31, 2019 | ~$10.6B | ~$1.7B | ~$105.2B | ~$81B | ~$15.1B | ~$8.9B | Form 20-F |
| FY2018ended Dec 31, 2018 | ~$11.1B | ~$1.8B | ~$76.6B | ~$71.8B | ~$5B | ~$9.3B | Form 20-F |
| FY2017ended Dec 31, 2017 | ~$9.1B | ~$2B | ~$74.4B | ~$69.8B | -~$89.8M | ~$7.1B | Form 20-F |
Keep researching GSK
GSK Revenue and Financial FAQ
What is the typical annual revenue and operating profit scale of GSK plc?
GSK plc reported revenue of ~$43.2 billion (£32.7 billion) for fiscal year 2025, up from ~$41.4 billion (£31.4 billion) in fiscal 2024.
How did the 2022 Haleon demerger strengthen GSK's balance sheet and reduce net debt?
The Haleon demerger provided GSK with over $9.24 billion (£7 billion) in gross cash dividend proceeds, allowing GSK to dramatically de-lever its balance sheet, reduce net debt from over $26.4 billion (£20 billion) down to approximately $17.2 billion (£13 billion) to ~$19.8 billion (£15 billion), and increase investment in biopharma R&D.
What is GSK's dividend policy and capital allocation framework?
GSK maintains a progressive, sustainable quarterly cash dividend payout targeted at a 40% to 60% payout ratio of adjusted earnings per share, balancing shareholder income with capital allocated toward targeted biopharma M&A and pipeline R&D.
How does Shingrix contribute to GSK's Vaccines segment revenue?
Shingrix is GSK's multi-billion-pound blockbuster shingles vaccine, generating over $4.49 billion (£3.4 billion) annually. With clinical efficacy exceeding 90% across age groups, Shingrix represents one of the most profitable vaccine franchises in pharmaceutical history.
How does GSK manage patent expirations and generic erosion across mature medications?
GSK proactively offsets generic erosion of older off-patent drugs by replacing them with high-growth specialty biopharma and vaccine blockbusters (such as Arexvy, Jemperli, and next-generation long-acting HIV cabotegravir regimens).
What are GSK's major research and development capital allocation priorities?
GSK prioritizes pipeline investment in infectious diseases (therapeutic hepatitis B cures, mRNA seasonal flu/COVID combination vaccines), specialty HIV therapies at ViiV, solid tumor and hematologic oncology, and targeted immunology therapies.
How do foreign exchange rate fluctuations impact GSK's reported financials?
Because GSK reports its financial statements in British Pounds (GBP) while generating more than half of its turnover in US Dollars (USD), a weakening Pound provides translation tailwinds to reported revenue and operating profits.
What is the financial performance and ownership structure of ViiV Healthcare within GSK?
ViiV Healthcare generates over $8.45 billion (£6.4 billion) in annual revenues. GSK owns a 78.3% majority equity stake (with Pfizer holding 11.7% and Shionogi 10%), consolidating ViiV's revenues and operating profits into GSK's financial statements while distributing minority shareholder dividends.
Does GSK own Advil and Sensodyne?
No longer. In 2022, facing massive pressure from activist investors to unlock value, GSK executed a massive corporate spin-off. They took their entire Consumer Healthcare division (which sold Sensodyne, Advil, and Tums) and launched it as an independent public company named Haleon, allowing GSK to focus purely on high-margin prescription drugs.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "GSK Revenue & Financials." CorpDigest, https://corpdigest.com/company/gsk/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>GSK reported ~$43.1B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/gsk/financials" target="_blank" rel="noopener">CorpDigest — GSK financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore GSK
Core profile pages, founders and related research hubs for this company.